Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.30 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.30 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27001873 | 1.00 | IL1RN (0.36) | IL1RNERAP2ERAP1KDM1AKDM1B | |
| SCHEMBL27001910 | 0.82 | HTR2C (0.31) | — | |
| SCHEMBL30635206 | 0.82 | HTR2C (0.31) | — | |
| SCHEMBL9024315 | 0.77 | DRD2 (0.44) | IL1RNERAP2ERAP1 | |
| SCHEMBL27001875 | 0.75 | — | — | |
| SCHEMBL27001903 | 0.75 | CRBN (0.43) | — | |
| SCHEMBL27133713 | 0.75 | CRBN (0.43) | — | |
| SCHEMBL25764036 | 0.75 | KDM1A (0.34) | IL1RNERAP2ERAP1KDM1AKDM1B | |
| SCHEMBL25764039 | 0.75 | KDM1A (0.34) | IL1RNERAP2ERAP1KDM1AKDM1B | |
| SCHEMBL15414676 | 0.74 | CMA1 (0.50) | KDM1AANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117083270-A | Heterocyclic RIP1 kinase inhibitors | 里格尔药品股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-09-22 | — | — | US | disclosed |
| WO-2022192533-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | IL1RN 201/4885ERAP2 2683/4885ERAP1 1812/4885 |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | IL1RN 201/4885ERAP2 2683/4885ERAP1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.